Loading organizations...
Peptomyc has raised $20.1M across 3 funding rounds.
Key people at Peptomyc.
Peptomyc has raised $20.1M in total across 3 funding rounds.
Peptomyc develops mini-protein therapeutics designed to directly inhibit MYC, a central driver of cancer proliferation and survival. The company's lead product, OMO-103, is a patented cell-penetrating mini-protein derived from Omomyc, engineered to overcome the historical challenge of drugging MYC and deliver a targeted anti-cancer effect by disrupting this crucial oncogene. This pioneering approach aims to selectively eradicate cancer cells while preserving healthy tissues.
The company emerged as a spin-off from the Vall d’Hebron Institute of Oncology (VHIO) and ICREA. Co-founder Dr. Laura Soucek, a recognized expert in MYC, designed Omomyc and demonstrated its therapeutic potential. Fellow co-founder Dr. Marie-Eve Beaulieu, a protein scientist, subsequently identified the cell-penetrating capabilities of the Omomyc mini-protein, providing the foundational insight for developing it into a clinically viable therapeutic for cancer treatment.
Peptomyc targets cancer patients experiencing abnormal MYC activity, aiming to provide a foundational treatment that improves patient survival and quality of life. The company envisions a future where cancer is a conquerable challenge, focusing on unlocking novel therapeutic avenues through its proprietary MYC inhibitory mini-proteins. Its long-term vision involves addressing high unmet medical needs and reshaping the standard of care in oncology.
Peptomyc is a clinical-stage biotech spin‑out developing cell‑penetrating mini‑protein therapeutics that directly inhibit the MYC oncoprotein, with a lead candidate (OMO‑103) that has completed Phase I and is advancing in Phase Ib/II studies for multiple solid tumors[1][3].
High-Level Overview
For the product/company focus in two short paragraphs:
Peptomyc builds cell‑penetrating mini‑protein therapeutics derived from the Omomyc mini‑protein to directly inhibit the MYC transcription factor, a central driver of cancer proliferation, survival, and therapy resistance[1][3]. The lead asset, OMO‑103, is presented as a first‑in‑class direct MYC inhibitor that has completed Phase I and is being tested in combination and disease‑specific trials (e.g., pancreatic cancer, osteosarcoma) while the company scales manufacturing and develops companion diagnostics[3][6][7].
Peptomyc’s approach targets a broad patient population across tumor types characterized by abnormal MYC activity rather than mutation‑specific subgroups, positioning the therapy as potentially applicable across many cancers where MYC is dysregulated[4][1].
2. Origin Story
Core Differentiators
Role in the Broader Tech and Therapeutics Landscape
Quick Take & Future Outlook
Quick take: Peptomyc is one of the most noteworthy anti‑MYC translation efforts—a small, academically rooted biotech that has already crossed the key milestone of human dosing with a first‑in‑class mini‑protein inhibitor and is now executing on combination and disease‑specific trials while scaling manufacturing and diagnostic capabilities[3][1]. Its success would be paradigm‑shifting for oncology; its near‑term fate depends on forthcoming clinical data and the company’s ability to industrialize a novel biologic modality[7][5].
Key people at Peptomyc.
Peptomyc has raised $20.1M across 3 funding rounds. Most recently, it raised $13.9M Other Equity in December 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 16, 2020 | $13.9M Venture Round | Guido Guidi | Alta Life Sciences, Business Angels, Cdti, Healthequity | Announced |
| Sep 7, 2017 | $5M Series A | Montserrat Vendrell | Healthequity | Announced |
| May 10, 2016 | $1.1M Venture Round | Healthequity | — | Announced |
Peptomyc has raised $20.1M in total across 3 funding rounds.
Peptomyc's investors include Guido Guidi, Alta Life Sciences, Business Angels, CDTI, HealthEquity, Montserrat Vendrell.